SK bioscience wins patent lawsuit against Pfizer over pneumococcal vaccine in Korea: Gyeonggi-do, Republic of Korea Friday, May 23, 2025, 10:00 Hrs [IST] SK bioscience, a global i ...

The U.S. Food and Drug Administration's advisory panel is set to vote on Thursday to recommend whether COVID-19 vaccines for ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

And the man’s mother in tears recalling her son, a Boston police officer whose death is at the heart of a trial gripping the nation. The first full day of testimony concluded on Wednesday.

Having already worked with clinical trial sites in more than 14 states, CTAC will now take its work nationwide, the ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Thanks to generous support and partnership from Alexandria Real Estate Equities, Inc., Fred Hutch has a new, state-of-the-art ...

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job ...